| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7649b77c98cdca3647fe825abf0b4402 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4015
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 |
| filingDate |
2006-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9872d2a3e14d9bb6a768647620962276
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e697f435ff8895a9daec875a20fcb6ff
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_10bcf79de8f92314ddaa0b8a51ca302f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5d19ecbbf46a652f30865cee9a2f50fb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_affc5d094bc4f0cf0a4454d2804badf0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4264695222b4e1cc07e9e4138880d600
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f55633069d13e9b00c30566fc9b53400 |
| publicationDate |
2008-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-101128196-A |
| titleOfInvention |
Combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases |
| abstract |
The present invention relates to a combination comprising topical (inhaled) anticholinergics and inhaled or oral leukotriene (LT) receptor antagonists (BLT- and CysLT-receptor antagonists) for the treatment of respiratory diseases including allergic rhinitis, bronchial asthma and chronic obstructive pulmonary diseases (COPD). It further comprises the presentation of this combination in a locally applied (inhaled) formulation and application in an inhalation device for instance in the Novolizer TM . |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113613657-A |
| priorityDate |
2005-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |